Radio Cadena Agramonte emisiora de Camagüey
Havana, Nov 30.- Chinese and Cuban specialists discussed today the latest advances in the fight against cervical cancer based on the use of Nimotuzumab.
As part of a scientific event at the island's Embassy here, Professor Li Xiaofan of Beijing Cancer Hospital presented the latest progress in using the drug in cervical cancer research.
Subsequently, Professor Jiang Ping introduced the protocol of a multicenter clinical study to evaluate the effectiveness of Nimotuzumab combined with chemoradiotherapy in patients with advanced squamous cell carcinoma.
The event included speeches by the Cuban ambassador to China, Alberto Blanco Silva, and Professor Wang Junjie, who highlighted the importance of international cooperation in the medical field.
Likewise, a discussion was held with specialists from various institutions, who exchanged experiences and perspectives on current treatments.
Researchers from China and Cuba stressed the relevance of sharing knowledge for the development of innovative therapies in the fight against this disease.
Previously, both countries addressed the use of Nimotuzumab against head and neck cancer during a program that included scientific presentations, debates and innovative strategies between academic leaders from prestigious medical institutions in China and specialists from the island.
In statements to Prensa Latina, Bai Xianhong, president of the joint venture Biotech Pharmaceuticals Limited (BPL), recalled the success of the Asian giant's first humanized monoclonal antibody.
Nimotuzumab provided efficient cancer treatment to more than 300,000 Chinese patients, he noted.
Likewise, the owner said that cooperation with Cuba will continue in the coming years, the joint venture will improve the production capacity of monoclonal antibodies and establish world-leading perfusion lines based on the culture of mammalian cells.
For her part, the deputy general director and representative of the Cuban vice presidency of BPL, Yanet Borrego, recalled that cooperation in biotechnology with China allowed the entry of Cuban products into the Asian giant's market and more and more Chinese patients can be treated with them.
Nimotuzumab is the leading product, it was recently registered in China for the treatment of head and neck cancer, and was previously used here to treat pancreatic and nasopharyngeal carcinoma, he told Prensa Latina.
As detailed, BPL is now focused on the development of nine other innovative products that are in the research and development phase, and should enter the market in about 10 years. (Text and photos: PL)
